Beyond Meat

Beyond Meat is the plant-based bellwether that has done the one thing distressed companies must do to survive: fix the balance sheet. Its 2026 convertible-notes exchange cut total debt from roughly $1.15B toward the low hundreds of millions, and Q1 2026 showed the operational turn the deleveraging was meant to buy time for — gross margin swung to a positive 3.4% from negative 10.1% a year earlier, the net loss narrowed to $28.5M, operating expenses fell to $43.1M from $57.4M, and the company held $205.8M in cash. Management guided Q2 revenue to roughly $60–65M and framed results as in line with expectations, with sequential improvement across margin, adjusted EBITDA, and cash burn. The 2026 rebrand to "Beyond The Plant Protein Company" signals a strategic widening beyond the crowded burger analogue into adjacent protein categories where the brand's name recognition — still the most valuable in the space — can travel. Beyond retains national retail and foodservice distribution, the Beyond Burger's shelf presence, and a founder-CEO in Ethan Brown who has kept the company alive through the category's brutal downcycle. As the only pure-play public name, any recovery in plant-based demand or successful category extension flows disproportionately to the stock that everyone watches.

The Q1 2026 numbers are less a turnaround than a controlled decline: revenue fell another 15.3% to $58.2M, driven by a 19.5% collapse in volume, meaning the "improved" margins came from selling far fewer units at higher prices — the opposite of the scale story a growth stock needs. Full-year 2025 revenue had already dropped about 16% to roughly $275.5M, and the company has flagged going-concern and liquidity risks even after restructuring. The debt exchange saved the balance sheet by savaging shareholders: it issued hundreds of millions of new shares, diluting existing holders massively, and $411.6M of debt still carried on the March balance sheet shows the deleveraging is incomplete. Beyond also received a Nasdaq delisting warning amid delayed filings. The core problem is demand, not capital structure: U.S. plant-based meat retail sales fell 7.5% in the year to April 2025 with volumes down 10%, a category in secular contraction as the health halo faded and repeat purchase stalled. A rebrand into "adjacent protein categories" is a pivot away from the very product that defined the company, into markets where it has no proven right to win. With a shrinking top line, a stack of newly issued shares, and a category in retreat, Beyond is deleveraged but not yet demonstrably viable.